@article{oai:repo.qst.go.jp:00084317,
 author = {Igarashi, Chika and Yoshii, Yukie and Tashima, Hideaki and Iwao, Yuma and Sakurai, Kohei and Hihara, Fukiko and Tachibana, Tomoko and Yoshida, Eiji and Wakizaka, Hidekatsu and Akamatsu, Go and Yamaya, Taiga and Yoshimoto, Mitsuyoshi and Matsumoto, Hiroki and Ming-Rong, Zhang and Nagatsu, Kotaro and Sugyo, Aya and Tsuji, Atsushi and Higashi, Tatsuya and Chika, Igarashi and Yukie, Yoshii and Hideaki, Tashima and Yuma, Iwao and Kohei, Sakurai and Fukiko, Hihara and Tomoko, Tachibana and Eiji, Yoshida and Hidekatsu, Wakizaka and Go, Akamatsu and Taiga, Yamaya and Hiroki, Matsumoto and Zhang, Ming-Rong and Kotaro, Nagatsu and Aya, Sugyo and Atsushi, Tsuji and Tatsuya, Higashi},
 issue = {10},
 journal = {Nuclear medicine communications},
 month = {Jun},
 note = {In pancreatic cancer surgery, accurate identification and resection of intrapancreatic residual tumors are quite difficult. We have developed a novel open-typed PET system (called 'OpenPET'), which enables high-resolution PET-guided surgery in real time, and demonstrated that OpenPET-guided surgery with intraperitoneally administered 64Cu-labeled anti-epidermal growth factor receptor antibody cetuximab is useful to detect and resect primary pancreatic cancer. Here, we investigated applicability of OpenPET-guided surgery for unexpected residual intrapancreatic tumors and examined its survival benefit over conventional surgery.},
 pages = {1112--1121},
 title = {Usefulness of PET-guided surgery with 64Cu-labeled cetuximab for resection of intrapancreatic residual tumors in a xenograft mouse model of resectable pancreatic cancer},
 volume = {42},
 year = {2021}
}